No Data
Teva Pharmaceuticals Presents 4th Interim Analysis Of PEARL Migraine Prevention Study At EAN Congress; New Sub-Analysis Highlights Potential Negative Impact Of Treatment Pauses On Patient Outcomes
New AJOVY (Fremanezumab) Migraine Prevention Data Challenges Treatment Pauses
Teva Pharmaceuticals Is Maintained at Buy by Jefferies
Jefferies Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $23
Teva Pharmaceutical Indus Analyst Ratings
Jefferies Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $23
Jefferies analyst Glen Santangelo maintains $Teva Pharmaceutical Industries(TEVA.US)$ with a buy rating, and adjusts the target price from $17 to $23.According to TipRanks data, the analyst has a succ